Tens of millions of people worldwide are now taking GLP-1 receptor agonists—semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and others—for weight management and type 2 diabetes. These medications have delivered results that were, until recently, unimaginable outside of surgery: participants in clinical trials routinely lose 15–20% of their body weight.

But a question lingers in nearly every clinic visit, every dinner table conversation, every comment section: What happens when I stop?